Evidence map›Paper›PMID 34692198›Full record

ArticleBiomedical optics express2021

Unveiling osteosarcoma responses to DAPT combined with cisplatin by using confocal Raman microscopy.

Jie Li, Jing Li, Haifeng Wang, Jie Qin, Haishan Zeng, Kaige Wang, Shuang Wang

Open access · goldAbstract read
In one paragraph

Article in Biomedical optics express, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. NOTCH Signaling in Osteosarcoma.Current issues in molecular biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jie LiInstitute of Photonics and Photon-Technology, Northwest University, Xi'an, Shaanxi 710069, China.
Jing LiDepartment of Orthopaedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China.
Haifeng WangInstitute of Photonics and Photon-Technology, Northwest University, Xi'an, Shaanxi 710069, China.
Jie QinDepartment of Orthopaedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China.
Haishan ZengImaging Unit-Integrative Oncology Department, BC Cancer Research Centre, Vancouver, BC, V5Z1L3, Canada.
Kaige WangInstitute of Photonics and Photon-Technology, Northwest University, Xi'an, Shaanxi 710069, China.ORCID https://orcid.org/0000-0001-6221-9954
Shuang WangInstitute of Photonics and Photon-Technology, Northwest University, Xi'an, Shaanxi 710069, China.ORCID https://orcid.org/0000-0002-5558-4029
Second Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to clarify the dose- and time-dependent effect of the γ-secretase inhibitor (DAPT) combined with cisplatin on osteosarcoma (OS) cells, evaluated by confocal Raman microspectral imaging (CRMI) technology. The intracellular composition significantly changed after combined drug action compared with the sole cisplatin treatment, proving the synergistic effect of DAPT combined with cisplatin on OS cells. The principal component analysis-linear discriminant analysis revealed the main compositional variations by distinguishing spectral characteristics. K-means cluster and univariate imaging were used to visualize the changes in subcellular morphology and biochemical distribution. The results showed that the increase of the DAPT dose and cisplatin treatment time in the combination treatment induced the division of the nucleus in OS cells, and other organelles also showed significant physiological changes compared with the effect of sole cisplatin treatment. After understanding the cellular response to the combined drug treatment at a molecular level, the achieved results provide an experimental fact for developing suitable individualized tumor treatment protocols.

Identifiers

PMID34692198
PMCPMC8515968
OpenAlexW3192249313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.